Medication info
Telmisartan/Amlodipine/Rosuvastatin 40/5/10 mg

Telmisartan/Amlodipine/Rosuvastatin 40/5/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Il Sung IS Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500557 · Approved 2025.03.13 · Insurance code 655404800

Summary

Main use
Treatment of hypertension and dyslipidemia; slowing the progression of atherosclerosis and reducing the risk of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue this diet throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg per day. 2. Older patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the rosuvastatin 40 mg dose is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC increased approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Il Sung IS Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; slowing the progression of atherosclerosis and reducing the risk of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not well controlled with a combination of telmisartan and amlodipine, while rosuvastatin is primarily used as an adjunct to diet in patients with hypercholesterolemia and hyperlipidemia. Rosuvastatin is effective for various lipid disorders such as primary hypercholesterolemia, familial hypercholesterolemia, and dysbetalipoproteinemia. Additionally, it helps reduce the risk of complications after stroke, myocardial infarction, and arterial revascularization in patients at high risk for cardiovascular diseases. This medication is used to improve cardiovascular health by simultaneously managing blood pressure and blood cholesterol levels.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take the tablet at the same time each day (e.g., in the morning). This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue this diet throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg per day. 2. Older patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the rosuvastatin 40 mg dose is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC increased approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to this medication's active ingredients or related substances, those with specific genetic disorders, severe liver dysfunction, or severe renal impairment should not take it. Particularly, patients with a history of angioedema or those taking certain medications may be at risk, so it is essential to consult a physician. Elderly patients or those with specific health conditions like hypertension or hyperkalemia should use it with caution, and it is important to monitor liver and kidney function periodically. If symptoms related to muscles such as myalgia, muscle weakness, or cramping occur during treatment, notify medical personnel immediately, and blood tests should be conducted if necessary to check for muscle damage. This medication may cause liver dysfunction, and liver enzyme levels should be monitored regularly; it should be discontinued if liver function deteriorates significantly. Because of possible interactions with other medications, inform healthcare providers about any current medications being taken. If breastfeeding, it is recommended to stop nursing while on this medication as it can be excreted in breast milk. Safety and efficacy have not been established in children under 18 years, so it is not recommended. In case of overdose, symptoms such as hypotension, cardiac irregularities, or renal function decline may occur, and appropriate treatment should be sought immediately at a medical facility. It is advised to keep this medication out of reach of children and not to transfer it to other containers.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, hiatal hernia, dysuria, rhinitis, pharyngeal discomfort, lung disease, unspecified gastrointestinal disorders, benign gastric neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, headache, dizziness, orthostatic hypotension, lower back pain, edema, flushing, palpitations, fatigue, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, burning sensation, malaise, rigidity, weight gain, weight loss, arthralgia, arthritis, muscle cramps, myalgia, erectile dysfunction, insomnia, nervousness, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, visual disturbances, conjunctivitis, diplopia, ocular pain, ear pain, frequent urination, urinary disorders, nocturnal enuresis, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, erectile dysfunction, diarrhea, myopathy, rhabdomyolysis, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, weakness, hypotension, hypoglycemia, syncope, urinary tract infection, increased sweating, erythema, atrial fibrillation, congestive heart failure, myocardial infarction, hypertension, hyperkalemia, muscle cramps, thrombocytopenia, increased serum creatinine, acute renal failure, oliguria, arthralgia, sensory disturbances, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, generalized pain, gout, gynecomastia, memory loss, polyneuropathy, peripheral neuropathy, cough, angioedema, vasculitis, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that blocks light. It is also important to store it at a cool room temperature, specifically between 1 and 30 degrees Celsius, to maintain its effectiveness.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.